Product name
Recombinant Human TWEAK Receptor protein
Code
CD00748
Biological activity
Fully biologically active when compared to standard. The ED50 as determined by inhibiting TWEAK-dependent proliferation of human umbilical vein endothelial cells (HUVEC) is less than 30 ng/ml, corresponding to a specific activity of > 3.3 × 104 IU/mg, in the presence of 15 ng/ml of rHuTWEAK.
Endotoxin
Less than 1 EU/μg of rHuTWEAK Receptor as determined by LAL method.
Synonyms
TWEAK Receptor,TNFSF12, CD266, FN14, TWEAKR,Human
Sequence
EQAPGTAPCS RGSSWSADLD KCMDCASCRA RPHSDFCLGC AAAPPAPFRL LWP
Uniprot Accession
Molecular Weight
Approximately 5.6 kDa, a single non-glycosylated polypeptide chain containing 53 amino acids.
Formulation
Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Background
Human TNF-related weak inducer of apoptosis receptor (TWEAKR) also known as Tumor necrosis factor receptor superfamily member 12A precursor (gene name TNFRSF12A) or fibroblast growth factor-inducable 14 kDa protein, is distantly related to the TNFR family, containing one cysteine-rich domain in the extracellular region and a TNFR-associated factor binding domain but does not contain a death domain (DD) cytoplasmic region. It is expressed in the spleen, thymus, peripheral blood lymphocytes, colon, and small intestine. Signal transduction by TWEAK receptor can be activated by either the membrane anchored or the soluble TWEAK. In addition, It plays a role in TWEAK-induced endothelial cell migration, proliferation, and angiogenesis. Human and mouse TWEAK R share 82 % a.a. sequence identity.
Storage
-20ºC
Research area
Immunology